Background Negative predictive value (NPV) of celiac disease (CD)-related human leukocyte antigens (HLA) DQ2 and DQ8 approaches 100 % in individual patients. However, studies evaluating its exclusionary utility in patient groups are lacking. Aim We aim to assess the performance of HLA testing when applied to patient groups with varying characteristics and propose evidence-based recommendations for its clinical use. Methods Demographic and clinical information was recorded in patients undergoing HLA testing. Using predetermined criteria, patients were classified as CD, non-CD, or indeterminate. Diagnostic yield of HLA testing was defined as the percentage of patients in whom CD could be excluded based on negative HLA test.
Both serological and histological methods currently recommended for diagnosis of CD have limitations. Approximately 5 % of CD patients can present with normal serum levels of IgA-tTG (seronegative CD) [17, 19, [21] [22] [23] . Small intestinal changes can be limited to intraepithelial lymphocytosis without the presence of duodenal villous atrophy (VA) (Marsh 1), which is a sensitive yet non-specific finding for CD [24] [25] [26] . VA can also be patchy [27] , leading to a false-negative histological evaluation. Conversely, VA can occur in conditions other than CD [28] . Additionally, institution of a gluten-free diet (GFD) leads to serological and histological remission, requiring reintroduction of dietary gluten for a period of 6-8 weeks before meaningful evaluation can be conducted [29] .
Nearly, all patients with CD express at least one of the two major histocompatibility complex (MHC) class 2 molecules (human leukocyte antigen (HLA) DQ2 and HLA DQ8) critical for pathogenesis of CD. Accordingly, the absence of the corresponding genes virtually excludes a diagnosis of CD with a very high negative predictive value (NPV), independent of dietary gluten content [30] [31] [32] [33] [34] [35] [36] [37] [38] . The positive predictive value of HLA DQ2/DQ8 is, however, limited as they can be present in approximately 40 % of the general population, most of whom will never develop CD [39, 40] .
Available literature on the clinical role of HLA testing in CD is limited to evaluations of risk gradients [41] [42] [43] , disease severity [43, 44] , and sex distribution [45] . HLA testing has also been studied as a screening tool in high-risk populations and as a diagnostic tool for CD in combination with serology [34, [46] [47] [48] [49] .
While a negative HLA test rules out CD in a given patient with almost 100 % certainty, there are limited data evaluating its ability to rule out CD (diagnostic yield) in groups of patients undergoing evaluation for CD. The objectives of this study were to determine the diagnostic yield of celiac HLA testing and to develop evidence-based recommendations regarding its utility in the evaluation of subsets of patients suspected to have CD.
Methods
This retrospective study was carried out at The Celiac Center at Beth Israel Deaconess Medical Center (BIDMC), which serves as a tertiary care referral center for patients with known, suspected, or complicated CD. HLA testing was performed on blood samples by high-resolution PCR using commercially available sequence-specific primers (DQB1 and DQA1: Invitrogen, Carlsbad, California; DQB1: Biotest Diagnostics Denville, NJ). Eight major alleles that encode HLA DQ2. 5 [50] [51] [52] . Quantitative IgAtTg testing was performed through INOVA diagnostics using ELISA technique. Absolute values of serum IgA-tTG were reported according to the manufacturer's cutoff as IU/ml and classified as follows: (1) normal (0-19 IU/ml), (2) borderline positive (20-39 IU/ml), and (3) positive ([39 IU/ml).
Detailed information regarding indications and results of HLA typing, demographics, symptoms at presentation, investigations, duration, and type of treatment including GFD and response to therapy were recorded for all patients undergoing testing for CD-related HLA genes. Based on predetermined criteria (Table 1) , patients were divided into those with CD, those in whom CD was confidently excluded (non-CD), and those in whom the diagnosis of CD remained indeterminate.
Fisher's exact test, Student's t test (for normally distributed data), and Mann-Whitney U test (for non-normally distributed data) were used to assess observed differences between variables. A p value \0.05 was considered to represent significance. The institutional review board at BIDMC approved this study.
Results

Demographics and Final Diagnosis
Two hundred and fifty-six patients underwent CD-related HLA testing between December 2007 and August 2011. The mean age at testing was 47.7 years (range 18-93 years). The mean age at symptom onset was 40.1 years (range 3-77 years), and 200 (78.1 %) patients were female. A comorbid autoimmune condition was present in 21.5 % patients, and none of the above-mentioned attributes were significantly different between HLApositive and HLA-negative subjects ( Table 2 ). Family history of CD was reported in 17.6 % patients and was more likely to be present in HLA-positive than HLAnegative individuals (23 vs. 10 %, p = 0.01) ( Table 2) .
Thorough evaluation of clinical and laboratory data led to a diagnosis of CD in 44 and exclusion of CD in 173 patients. A final diagnosis was not possible in 39 patients of which 31 initiated GFD prior to definitive diagnosis and refused gluten challenge.
Frequency of Celiac-Related HLA Genotypes
Of the 256 patients included in this study, CD-related HLA DQ2 or DQ8 were absent in 40 % (100 non-CD ? 2 CD) patients with an overall diagnostic yield of 39 % and NPV of 98 %. 154 (60 %) patients were found to carry CD permissive HLA DQ2 and/or DQ8, of which 107 (69.5 %) were DQ2 positive, 39 (25.3 %) were DQ8 positive, and 8 (5.2 %) patients tested positive for both HLA DQ2 and DQ8.
Forty-two (27 %) HLA-positive and 2 (2 %) HLAnegative patients were diagnosed with CD. Hence, 42 of 44 (95.5 %) CD patients tested positive for one or more permissive HLA genes: 29 (66 %) CD patients were DQ2 positive, 9 (20.5 %) CD patients were DQ8 positive, and 4 (9 %) CD patients were positive for DQ2 and DQ8 alleles. 2 (4.5 %) CD patients tested negative for all conventional genotypes, but tested positive for half of the DQ2.5-trans genotype (DQA 0505 /DQB 0301 ).
Histological and Laboratory Data
Of the 256 patients, IgA-tTG levels and duodenal biopsy were checked in 202 and 178 patients, respectively, while on a gluten-containing diet. HLA-positive patients were significantly more likely to have positive serology (33.6 vs. 
Diagnostic Yield of HLA Testing in Various Subgroups
For calculation and comparison of indication-specific diagnostic yields of HLA testing, patients were divided into five major groups based on results of initial serologic and histological evaluation. The diagnostic yields of these major groups as well as various subgroups are summarized in Table 3 .
Group 1: Patients with Abnormal Histology and Increased IgA-tTG While Consuming Gluten
There were 43 patients in this group: Thirty-five patients had VA and eight patients had Marsh 1 histology. Three patients each with VA and Marsh 1 histology were HLA negative. CD was ruled out in all three HLA-negative Marsh 1 patients. Among the three HLA-negative patients with VA, CD was ruled out in just one patient with borderline positive IgA-tTG. CD was diagnosed in the two remaining HLA-negative patients with VA. The diagnosis was supported by positive IgA-tTG (Anti-tTG [ 2 9 ULN) and histological response to GFD in both these patients. Both patients were reported to be HLA DQ2/DQ8 negative by the testing laboratory but carried half of the DQ 2.5-trans genotype (DQA 0505 /B 0301 ). Overall CD was diagnosed in 34 patients, confidently ruled Non-celiac causes of VA seen in this group included common variable immune deficiency, small intestinal bacterial overgrowth, autoimmune enteropathy, collagenous sprue, peptic duodenitis, and eosinophillic gastroenteritis. The HLA genotypes associated with the abovementioned causes of non-celiac VA are presented in Table 4 . Alternative causes of intraepithelial lymphocytosis seen in this group included small intestinal bacterial overgrowth, Helicobacter pylori infection, and peptic duodenitis.
Group 4: Patients with Normal Histology and Increased IgA-tTG While Consuming Gluten
Of the 16 patients in this group, 9 and 7 patients, respectively, had positive and borderline positive IgA-tTG. HLA testing was negative in two (22.2 %) patients with positive and two (28.6 %) with borderline positive IgA-tTG, giving Table 3 .
Discussion
While the genetics of CD are considered to be multifactorial [53] , HLA DQ2 and DQ8 genes remain the most important genetic factors and are responsible for up to 40 % of the genetic heritability of CD as compared to other known associated genes that are collectively responsible for approximately 5 % heritability [40, 53] . With a NPV approaching 100 %, HLA testing provides critical information in the evaluation of patients with suspected CD where the serological, histological, and clinical pictures are discrepant and in those where standard modalities of testing are not applicable due to prior institution of a GFD. However, despite clear utility of celiac HLA testing in individual patients, data on diagnostic yield for specific clinical indications are limited, contributing to both underuse and misuse of this test. It is notable that while the cost of HLA testing is high (approximately $350 at our center) when compared to IgA-tTG, it is much lower than endoscopy with duodenal biopsy and histological evaluation (approximately $2,000). Endoscopy is also invasive and carries associated risks and patient burden in contrast to HLA testing. Given these estimated costs, in situations where negative HLA testing obviates the need for endoscopy and biopsy, the diagnostic yield of HLA testing needs only to be greater than 18 % to be cost effective.
As expected, the frequency of DQ2 alleles (DQ2.5) was highest in CD patients followed by those with DQ8 genotype, and a small fraction were positive for both DQ2 and DQ8 genotype. A small fraction (N = 2) of CD patients were DQ2.2 positive. Also, there were no significant differences between DQ2-positive and DQ8-positive patients in terms of disease phenotype or demographics (results not presented).
In our evaluation, we found that the 256 patients who underwent testing for CD-related HLA genes could be subdivided into five major categories based on histological and serological abnormality. The diagnostic yield of testing, defined as the percent of patients in which negative HLA testing lead to the exclusion of CD, varied widely within the groups (Table 3) .
Seronegative CD occurs in approximately 5 % of all patients with CD and can present a diagnostic dilemma. In patients with VA with normal IgA-tTG, negative HLA testing (27.6 %) allowed the important differentiation between seronegative CD and non-celiac enteropathy [28, 54] .
Our data also highlight the utility of HLA testing in nonceliac gluten sensitivity, which is increasingly encountered in clinical practice [55, 56] . Given the sharp increase in awareness of non-celiac gluten sensitivity [57] , a high rate (3.24-34.9 %) of self-reported food sensitivity in the Western population [58] , and the improved availability of gluten-free options, it is not uncommon for patients to initiate GFD before presenting to a healthcare provider. The finding that a substantial number of patients on a GFD without a diagnosis of CD were negative for HLA DQ2 and DQ8 (46.4 %) is in line with previous reports [59] . A diagnostic yield of close to 50 % in this group supports HLA testing as an efficient initial step in evaluation prior to considering gluten challenge in patients where institution of GFD precludes serological and histological exclusion of CD.
Approximately 7-30 % CD patients fail to respond to GFD and are considered as having non-responsive CD (NRCD) [60] . In this study, approximately 20 % of such patients were found to lack CD-related HLA DQ2 and DQ8. This suggests that HLA testing can be considered early in the evaluation of NRCD; however, further study in this area is needed.
In patients groups with low diagnostic yield for HLA testing but high risk of developing CD such as those with normal histology and positive serology [61, 62] or negative serology with positive family history HLA testing may provide a cost benefit.
Almost all CD patients are positive for HLA DQ2.5, DQ2.2, or DQ8. However, this general rule is not absolute and occasional exceptions have been reported in the literature. Best documented is the occurrence of CD in individuals carrying the HLA DQ2.5-cis a allele DQA 0501 in the absence of the b allele. In this study, we identified two subjects with CD who were negative for DQ2.5, DQ2.2, and DQ8. However, the contributing alleles were different to those previously reported in that they represent half of the DQ2. 5 While we feel that our results are robust and reflective of standard practices regarding HLA testing in CD, we recognize the limitations that this is a retrospective study, conducted in a single referral center, and that the absence of HLA DQ2 and DQ8 does not exclude CD in 100 % of cases. While our five main groups were large enough to allow data generation and extrapolation, same is not true for some of the subgroups. This is probably secondary to the scarcity of patients with those particular traits.
In conclusion, the yield of HLA testing for exclusion of CD varies significantly depending on the clinical indication. A negative HLA result usually obviates the need for further celiac testing including possible endoscopy and gluten challenge. HLA testing can be a critical and cost-effective diagnostic modality. Diagnostic yield of HLA needs to be higher than 18 % in a group of patients for the testing to be cost effective. In patients with very high pretest probability for CD, who test negative for HLA DQ2.5, DQ2.2, and DQ8, certain DQ2.5 alleles, either in cis (DQA 0501 ) or trans (DQA 0505 /DQB 0301 ) configuration should be sought as these may rarely confer CD susceptibility. The data presented in this study should assist in the effective use of HLA testing in CD evaluation.
